Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Cancer Trial Endpoints: Minimal Residual Disease Eyed As Surrogate

Executive Summary

More work needs to be done to validate MRD as predictive of clinical outcomes in hematological malignancies before it can be used as the basis for accelerated approval, FDA and other stakeholders say.


Related Content

Duke's McClellan: Changing Drug Development Policy From Outside FDA
Roche Oncology Trials Designed For “Learning On The Go”
Roche’s Master Plan: Perjeta Gains Early Breast Cancer Approval, Late-Stage Kadcyla Data
Minimal Residual Disease Endpoint Would Aid Leukemia Drug Development, Experts Say
FDA Breast Cancer Guidance Paves Way For Accelerated Approval With One Trial


Related Companies